Jump to content
Reading list

Sensitivity, movement and hormone papers

The papers gathered together, with their own titles intact.

Sensitivity, surgery and emesis

For the site’s starting question, there is the rat visceral-and-somatic sensitivity experiment. The adult bowel-resection trial supplies the clinical disappointment that matters to the movement story. The ferret cisplatin study gives weight preservation and vomiting separate answers.

The endocrine papers explain why a compound introduced through growth-hormone release appears in this company. One item further below concerns GSK894281, a different ghrelin-receptor agonist tested in rats; that toxicology finding is discussed with its identity attached on the hormone page.

  1. Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics ↗
  2. Ipamorelin, the first selective growth hormone secretagogue ↗
  3. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus ↗
  4. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders ↗
  5. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients ↗
  6. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism ↗
  7. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
  8. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist ↗